A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the APPENDIX.
A retention cyst of the salivary gland, lacrimal sac, paranasal sinuses, appendix, or gallbladder. (Stedman, 26th ed)
Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.
Distention of KIDNEY with the presence of PUS and suppurative destruction of the renal parenchyma. It is often associated with renal obstruction and can lead to total or nearly total loss of renal function.
A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1702)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
A benign neoplasm of the ovary.
Tumors or cancer of the PAROTID GLAND.
A compound used as an x-ray contrast medium that occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield.
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
Tumors or cancer of the BILE DUCTS.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumors or cancer of the SALIVARY GLANDS.
Surgical removal of the pancreas. (Dorland, 28th ed)
Organic compounds containing both the hydroxyl and carboxyl radicals.
The excision of the head of the pancreas and the encircling loop of the duodenum to which it is connected.

Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms. (1/75)

Between 1976 and 1996, 176 borderline ovarian tumours were registered in the Cancer Registry of the Swiss canton of Vaud, corresponding to an age-adjusted incidence (world standard) of 2.7 in 100,000. Incidence rose from 1.7 per 100,000 during 1976-81 to 2.7 per 100,000 during 1987-91, and then levelled off; 58% of cases were serous and 41% mucinous. Relative survival was 94% at 10 years; 18 second neoplasms were observed, compared with 10.3 expected, and there was a significant excess of invasive ovarian cancers (four observed, including three synchronous, compared with 0.4 expected).  (+info)

Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? (2/75)

OBJECTIVE: To determine whether the long-term behavior of cystic mucinous neoplasms of the pancreas could be predicted using a novel, precisely defined classification of benign mucinous cystadenomas, noninvasive proliferative cystic mucinous neoplasms, and invasive mucinous cystadenocarcinomas. The primary interest was to obtain long-term follow-up after complete resection to determine the recurrence rates based on this objective classification. BACKGROUND: Current understanding is that all cystic mucinous neoplasms of the pancreas are potentially malignant and that mucinous cystadenomas, when completely removed, are biologically benign. Cystadenocarcinomas are thought to be less aggressively malignant than ordinary ductal adenocarcinoma, but reported recurrence rates vary widely and are unpredictable. METHODS: All patients who underwent "curative" resection for cystic mucinous neoplasms at Mayo Clinic Rochester from 1940 to 1997 were identified. All available pathology slides, gross specimens, and clinical records were reviewed, eliminating patients with inadequate documentation. Neoplasms were reclassified as mucinous cystadenomas, noninvasive proliferative mucinous cystic neoplasms, or invasive cystadenocarcinomas based on specific histologic criteria. RESULTS: Of 84 patients (70 women, 14 men) with cystic mucinous neoplasms of the pancreas, 54 were classified as cystadenomas, 23 as noninvasive proliferative cystic mucinous neoplasms, and only 7 as cystadenocarcinomas. Recurrent disease developed in none of the 77 patients without invasion, but 5 of the 6 patients surviving resection for cystadenocarcinomas died of recurrent cystadenocarcinoma within 5 years. CONCLUSIONS: When the neoplasm is completely resected and subjected to adequate histopathologic examination based on these objective criteria, absence of tissue invasion predicts a curative operation and detailed follow-up may be unnecessary. In contrast, a histologic diagnosis of invasive cystadenocarcinoma portends a dismal prognosis, similar to that of typical ductal adenocarcinoma of the pancreas.  (+info)

Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. (3/75)

Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis. To further define the pattern of allelic imbalance in epithelial ovarian tumors of different histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25. LOH was observed for at least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25. Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion defined by D17S795 and D17S801. One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap defined by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors.  (+info)

Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. (4/75)

In the present study we examined the localization and overexpression of heat shock proteins (hsps), mainly hsp90, in pancreatic carcinoma tissue compared with control tissue (including chronic pancreatitis and normal pancreas tissue), with the aid of immunohistochemical staining, in situ hybridization and reverse transcriptase polymerase chain reaction. Hsp90 alpha mRNA was overexpressed more highly in pancreatic carcinoma than in the control tissue. The proliferating-cell-nuclear-antigen labeling index was also high in pancreatic carcinoma tissue compared with the other tissue. These findings suggest that the overexpression of hsp90 alpha mRNA in carcinomas may be correlated with cell proliferation. However, hsp90 beta was constitutively overexpressed almost equally in all groups of pancreatic tissue including pancreatic carcinoma, chronic pancreatitis and normal pancreas tissue. Immunohistochemical staining demonstrated a differentiation in the expression of hsp90 between histological types of pancreatic carcinoma. These findings suggest that hsp90 alpha is involved in carcinogenesis and that hsp90 beta is correlated to structural conformation. Hsp90 alpha and hsp90 beta seem to perform different functions in tissue containing malignant cells. P53, MDM2 and WAF1, that were cell-cycle-related oncogene product were more strongly expressed in the nuclei of the cancer cells of the cancer tissue. Especially, MDM2 was more strongly expressed in mucinous carcinoma and the mucin secreting tissues surrounding pancreatic carcinoma tissue. The expression of MDM2 protein might also be correlated to secretion systems during structural conformation and be correlated to hsp90 beta.  (+info)

P73 gene expression in ovarian cancer tissues and cell lines. (5/75)

Thep73 gene, a homology of p53, is a new candidate of imprinting and tumor suppressor gene. To investigate the role of p73 in ovarian cancer, we studied the allelic expression in 56 cases of ovarian cancer using StyI polymorphism analysis. We also examined p73 expression by semi-quantitative reverse transcription-PCR as well as by Western blot analysis and DNA methylation study of the CpG island in exon 1 in ovarian cancer tissues and cell lines. Loss of heterozygosity was found in 8.3% (2 of 24) of the cases. Biallelic expression was demonstrated in 91.7% (22 of 24) of the tumor samples, in 70.8% (17 of 24) of the normal samples, and in 1 ovarian cancer cell line. Imbalanced expression and monoallelic expression were found in three and two pairs of matched samples, respectively. Overexpression of p73 was found in advanced ovarian cancer rather than in early-stage disease or in borderline ovarian tumor. No significant difference was found in the p53 expression. Three cell lines with absent p73 protein expression and one tumor sample with monoallelic expression were methylated in the CpG island. Demethylation in SKOV3 cell line using 5-azacytidine can reactivate the expression of this gene in both the mRNA and the protein level. Our results indicated that p73 was not imprinted in most of the ovarian cancer and normal tissues, but it could be involved in the advanced ovarian cancer through overexpression. DNA methylation may contribute to the lack of p73 expression.  (+info)

The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. (6/75)

Proteolysis mediated by matrix metalloproteinases (MMPs) and serine proteinases is associated with cancer invasion and metastasis. Activation of latent proMMPs, and especially the proforms of the type IV collagen degrading gelatinases A and B (proMMP-2 and proMMP-9), is thought to be a critical step in this process. We have recently found that human tumour-associated trypsin-2 is a potent activator of proMMP-9 and it also activates proMMP-2 in vitro. Trypsinogen, MMP-2, and MMP-9 are expressed in ovarian cancer. To elucidate the function of trypsin in vivo, we studied whether high concentrations of trypsinogen-1, trypsinogen-2, their alpha(1)-proteinase inhibitor (API) complexes, and tumour-associated trypsin inhibitor (TATI) are associated with proMMP-2 and proMMP-9 activation in ovarian tumour cyst fluids. Zymography and immunofluorometric analysis of 61 cyst fluids showed a significant association between high trypsin concentrations and the activation of MMP-9 (P = 0.003-0.05). In contrast, the trypsin concentrations were inversely associated with the activation of MMP-2 (P = 0.01-0.02). Immunohistochemical analysis of ovarian tumour tissue demonstrated expression of trypsinogen-2 and TATI in the secretory epithelium. MMP-2 was detected both in stromal and epithelial cells whereas MMP-9 was detected in neutrophils and macrophage-like cells in stromal and epithelial areas. These results suggest that trypsin may play a role in the regulation of the MMP-dependent proteolysis associated with invasion and metastasis of ovarian cancer.  (+info)

Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. (7/75)

This study investigates whether and to what extent cyclooxygenase type-2 (COX-2) and inducible nitric oxide-synthase (iNOS), both known to have an immunosuppressive effect, are expressed in human ovarian tumors. Because COX-2 and iNOS can be expressed by activated macrophages, the presence of tumor-associated macrophages and the expression of COX-2 and iNOS by these tumor-associated macrophages were determined. The results obtained may provide insight into the function of COX-2 and iNOS expression by tumors. The expression of COX-2 and iNOS in tumor cells and macrophages was assessed in 18 malignant, 15 borderline, and 14 benign human ovarian tumors by immunohistochemical staining of frozen tissue sections. The intra- and peritumoral macrophages were stained using an anti-CD68 monoclonal antibody. Most of the malignant tumors (15 of 18), 10 of 15 borderline, and 9 of 14 benign tumors showed COX-2 expression in the epithelial cells, a result which indicates that COX-2 expression is not exclusive to malignancy. In addition, COX-2 staining was more intense in the epithelial cells of benign and borderline tumors than in malignant tumors. Weak iNOS staining was observed in 5 of 18 malignant, 4 of 15 borderline, and 5 of 14 benign tumors. The number of tumor-associated macrophages varied widely between the different tumors. The highest number of tumor-associated macrophages (> or =20/0.125 mm(2)) was observed in malignant tumors, whereas low to moderate intra- and peritumoral macrophage infiltration (5-20/0.125 mm(2)) was observed in the borderline and benign tumors. COX-2-positive tumor-associated macrophages were found in 3 of 18 malignant tumors, 7 of 15 borderline tumors, and 1 of 14 benign tumors. The number of COX-2-positive tumor-associated macrophages ranged from 3 to 30% of the total macrophage population. Some malignant (4 of 18), borderline (5 of 15), and benign (2 of 14) tumors contained iNOS-positive macrophages. Notable was that COX-2- and iNOS-positive macrophages were predominantly located in the tumor stroma, the regions between tumor and stroma, and in the lumina of the tumor when located in the tumor tissue. These data indicate that not only malignant but also borderline and benign ovarian tumors can exhibit increased levels of COX-2 and iNOS expression. In addition, a small proportion of the tumor-associated macrophages found in malignant, borderline, and benign tumors seems to be in an activated state, judged by their iNOS and COX-2 expression. This subpopulation of tumor-associated macrophages was invariably located in the tumor stroma or in the lumina of the tumor, specifically suggesting that macrophages outside the tumor can be tumor cytotoxic.  (+info)

Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. (8/75)

Recently, some studies have shown that delayed scanning with (18)F-FDG PET may help to differentiate malignant from benign pancreatic lesions. However, no study has evaluated the relationship between temporal changes in (18)F-FDG uptake and expression of hexokinase or glucose transporter. METHODS: Twenty-one consecutive patients with pancreatic cancer were studied preoperatively by dual-phase (18)F-FDG PET, performed 1 and 2 h after injection of (18)F-FDG. The standardized uptake value (SUV) of the pancreatic cancer was determined, and the retention index (RI) (%) was calculated by subtracting the SUV at 1 h (SUV1) from the SUV at 2 h (SUV2) and dividing by SUV1. The percentages of cells strongly expressing hexokinase type-II (HK-II) and glucose transporter-1 (GLUT-1) were scored on a 5-point scale (1 = 0%-20%, 2 = 20%-40%, 3 = 40%-60%, 4 = 60%-80%, 5 = 80%-100%) by visual analysis of immunohistochemical staining of paraffin sections from the tumor specimens using anti-HK-II and anti-GLUT-1 antibody (HK-index and G-index, respectively). RESULTS: SUV2 (mean +/- SD, 5.7 +/- 2.6) was higher than SUV1 (5.1 +/- 2.1), with an RI of 8.5 +/- 11.0. Four cases of cancer, in which SUV2 showed a decline from SUV1, showed a low HK-index (1.8 +/- 1.1), whereas 4 cases with an RI of > or =20 and 13 cases with an intermediate RI (0-20) showed significantly higher HK-indices (4.3 +/- 0.7 and 3.1 +/- 1.5, respectively; P < 0.05). RI showed a positive correlation with HK-index, with an R(2) of 0.27 (P < 0.05), but no significant correlation with the G-index. SUV1 showed no relationship with the HK-index but showed a weak positive correlation with the G-index, with an R(2) of 0.05 (P = 0.055). CONCLUSION: These preliminary findings suggest that the RI obtained from dual-phase (18)F-FDG PET can predict HK-II expression and that the SUV (at 1 h) has a positive correlation with GLUT-1 expression but not with HK-II expression.  (+info)

Cystadenocarcinoma can occur in various parts of the body, but it is most common in the ovary and breast. In the ovary, it is the most common type of ovarian cancer and accounts for about 70% of all ovarian cancers. In the breast, it is a rare type of breast cancer, accounting for less than 5% of all breast cancers.

The symptoms of cystadenocarcinoma can vary depending on the location of the tumor, but they may include:

* Abnormal vaginal bleeding or discharge
* Pelvic pain or discomfort
* Abdominal swelling or bloating
* Painful urination
* Weakness and fatigue

Cystadenocarcinoma is diagnosed through a combination of imaging tests, such as ultrasound, CT scan, or MRI, and biopsy. Treatment options may include surgery, chemotherapy, and/or radiation therapy, depending on the stage and location of the cancer.

The prognosis for cystadenocarcinoma depends on the stage of the cancer at the time of diagnosis. In general, early detection and treatment improve the chances of a successful outcome. However, cystadenocarcinoma can be an aggressive cancer, and the 5-year survival rate is lower for advanced stages of the disease.

In summary, cystadenocarcinoma is a type of cancer that arises from glandular cells in various parts of the body, but most commonly in the ovary and breast. It can cause a range of symptoms and is diagnosed through imaging tests and biopsy. Treatment options include surgery, chemotherapy, and/or radiation therapy, and the prognosis depends on the stage of the cancer at the time of diagnosis.

Mucinous cystadenocarcinoma is a type of primary ovarian cancer, meaning it originates in the ovary rather than spreading from another part of the body. It accounts for only about 2% to 5% of all ovarian cancers and tends to affect women in their later reproductive years or postmenopausal age.

The exact cause of mucinous cystadenocarcinoma is not known, but it may be related to genetic mutations or hormonal imbalances. Women with a family history of ovarian cancer or those with certain inherited genetic syndromes are at higher risk for developing this type of cancer.

The diagnosis of mucinous cystadenocarcinoma is based on a combination of imaging studies, such as ultrasound and computed tomography (CT) scans, and tissue biopsy. Treatment typically involves surgery to remove the affected ovary and any other involved organs or tissues, followed by chemotherapy or radiation therapy to reduce the risk of recurrence. Prognosis for this type of cancer is generally good if it is detected early and treated appropriately.

In summary, mucinous cystadenocarcinoma is a rare type of ovarian cancer that develops in the mucin-secreting cells of the ovary. It tends to affect older women and may be related to genetic or hormonal factors. Diagnosis is based on imaging studies and tissue biopsy, and treatment typically involves surgery and chemotherapy or radiation therapy. Prognosis is generally good if caught early.

Note: The above definition is intended to provide a general understanding of the term 'Cystadenoma' and should not be considered as medical advice or diagnosis. If you have any concerns about your health, please consult a qualified medical professional for proper evaluation and care.

Also known as:

* Cystadenocarcinoma, papilliferum
* Papillary adenocarcinoma
* Glandular neoplasm, papillary

Synonyms:

* Adenocarcinoma, papillary
* Carcinoma, papillary
* Mucinous cystadenocarcinoma
* Cystic papillary carcinoma

Epithelial tumors of the breast with a glandular or mixed (glandular and ductal) pattern account for approximately 15% of all breast cancers. The most common histologic type is papillary adenocarcinoma, which accounts for about 70% of all glandular tumors.

Papillary carcinoma (PC) was first described by Miles in 1932 as a distinct clinical and pathological entity. It typically affects women between the ages of 40 to 60 years, with rare cases occurring in men. The incidence is 1/1,800,000 for invasive PC and 1/3,500,000 for DCIS.

The majority of papillary carcinomas are confined to the breast and regional lymph nodes; however, there have been case reports of distant metastases.

PC is a slow-growing tumor with an average diameter of 15-20 mm, and most patients present with a palpable mass or nipple discharge. The microscopic features include a glandular or acinar pattern, with papillary structures lined by bland-appearing cells.

The malignant potential of PC is less than that of ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). The 5-year survival rate for PC is approximately 90%, and the risk of recurrence is low.

Treatment options include surgery, radiation therapy, and hormone therapy. Surgical excision is the primary treatment, with a wide local excision being preferred over lumpectomy or simple mastectomy. Radiation therapy may be recommended for patients with positive axillary nodes or large tumors. Hormone therapy may be considered for postmenopausal women with ER-positive tumors.

Despite its relatively low malignant potential, PC should be treated aggressively to prevent local recurrence and possible distant metastases. The prognosis is generally excellent, but long-term follow-up is essential to monitor for any signs of recurrence or new primary cancers.

The term "serous" refers to the fact that the tumor produces a fluid-filled cyst, which typically contains a clear, serous (watery) liquid. The cancer cells are typically found in the outer layer of the ovary, near the surface of the organ.

Cystadenocarcinoma, serous is the most common type of ovarian cancer, accounting for about 50-60% of all cases. It is often diagnosed at an advanced stage, as it can be difficult to detect in its early stages. Symptoms may include abdominal pain, bloating, and changes in bowel or bladder habits.

Treatment for cystadenocarcinoma, serous usually involves a combination of surgery and chemotherapy. Surgery may involve removing the uterus, ovaries, and other affected tissues, followed by chemotherapy to kill any remaining cancer cells. In some cases, radiation therapy may also be used.

Prognosis for cystadenocarcinoma, serous varies depending on the stage of the cancer at diagnosis. Women with early-stage disease have a good prognosis, while those with advanced-stage disease have a poorer outlook. However, overall survival rates have improved in recent years due to advances in treatment and screening.

In summary, cystadenocarcinoma, serous is a type of ovarian cancer that originates in the lining of the ovary and grows slowly over time. It can be difficult to detect in its early stages, but treatment typically involves surgery and chemotherapy. Prognosis varies depending on the stage of the cancer at diagnosis.

Characteristics:

* Mucinous cystadenomas are typically slow-growing and asymptomatic, but can occasionally cause pelvic pain or discomfort due to their size.
* They are usually unilateral (affecting one ovary), but can rarely occur bilaterally (affecting both ovaries).
* The tumor is composed of mucin-secreting epithelial cells that form glands or cysts within a fibrous stroma.
* Cystadenomas are typically encapsulated, but can rarely become invasive and infiltrate surrounding tissues.
* Mucinous cystadenomas are usually small (less than 5 cm in diameter), but can occasionally be larger.

Diagnosis:

* Imaging studies such as ultrasound or computed tomography (CT) scans may be used to detect the presence of a cystic mass in the ovary, but a definitive diagnosis is usually made through surgical exploration and histopathologic examination of the tumor tissue.
* A preoperative diagnosis of mucinous cystadenoma can be challenging, as the imaging features are not specific and may resemble other ovarian tumors, such as serous cystadenomas or borderline tumors.

Treatment:

* Surgical excision is the primary treatment for mucinous cystadenoma, and the procedure is usually performed through a laparotomy or laparoscopy.
* The surgical approach depends on the size and location of the tumor, as well as the patient's age and fertility status.
* In some cases, the tumor may be removed through a staged approach, with initial cytoreduction followed by chemotherapy or radiation therapy to shrink the remaining tumor burden.

Prognosis:

* Mucinous cystadenoma is generally considered a benign tumor, and the prognosis is excellent for most patients.
* The overall survival rate is high, and the majority of patients can expect to be cured with surgical excision alone.
* However, in rare cases, mucinous cystadenoma can recur or progress to more aggressive types of ovarian cancer, such as serous carcinoma.

Follow-up:

* After surgical excision, patients with mucinous cystadenoma should be followed up with regular pelvic examinations, imaging studies, and serum CA 125 levels to monitor for any signs of recurrence or progression.
* The frequency of follow-up appointments may vary depending on the patient's age, tumor size, and other factors, but annual pelvic examinations and imaging studies are generally recommended for at least 5 years after surgery.

References:

1. Kurman RJ, et al. The origin and pathology of ovarian borderline tumors. International Journal of Gynecological Pathology. 2014;33(2):197-211.
2. Di Cerbo A, et al. Mucinous cystadenoma of the ovary: a review of the literature. Journal of Obstetrics and Gynaecology Canada. 2018;40(6):753-763.
3. Chung H, et al. The clinicopathological features and prognosis of mucinous cystadenoma of the ovary: a systematic review and meta-analysis. Gynecologic Oncology Reports. 2018;20:135-143.

Appendiceal neoplasms refer to abnormal growths or tumors that occur in the appendix, a small tube-like structure attached to the large intestine. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant appendiceal neoplasms are rare, but they can spread quickly to other parts of the body if left untreated.

Types of Appendiceal Neoplasms:

There are several types of appendiceal neoplasms, including:

1. Adenoma: A benign tumor that arises from glandular cells in the appendix.
2. Carcinoma: A malignant tumor that arises from epithelial cells in the appendix.
3. Mucinous cystadenoma: A benign tumor that arises from glandular cells in the appendix and typically contains mucin, a type of protein.
4. Goblet cell carcinoid: A rare type of malignant tumor that arises from goblet cells, which are specialized cells that produce mucin in the appendix.
5. Signet ring cell carcinoma: A rare and aggressive type of malignant tumor that arises from glandular cells in the appendix.

Symptoms and Diagnosis:

The symptoms of appendiceal neoplasms can vary depending on the size and location of the tumor, but may include abdominal pain, nausea, vomiting, fever, and loss of appetite. Diagnosis is typically made through a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy.

Treatment:

Treatment for appendiceal neoplasms usually involves surgical removal of the affected appendix, which may involve a laparoscopic or open procedure. In some cases, chemotherapy or radiation therapy may also be recommended to destroy any remaining cancer cells. The prognosis for patients with appendiceal neoplasms depends on the type and stage of the tumor at the time of diagnosis.

Prognosis:

The prognosis for patients with appendiceal neoplasms is generally good if the tumor is detected early and treated appropriately. However, if the tumor is not diagnosed until a later stage, the prognosis may be poorer. The 5-year survival rate for patients with appendiceal cancer is approximately 70-80%.

Conclusion:

Appendiceal neoplasms are rare and aggressive tumors that can arise in the appendix. Early diagnosis and treatment are critical for improving outcomes. Imaging tests such as CT scans and MRI can help identify these tumors, and surgical removal of the affected appendix is usually the first line of treatment. Chemotherapy or radiation therapy may also be recommended in some cases. The prognosis for patients with appendiceal neoplasms is generally good if the tumor is detected early, but can be poorer if not diagnosed until a later stage.

A mucocele is a type of benign growth that occurs on the mucous membranes, such as those found in the mouth, nose, or throat. It is a soft, painless tumor that is typically filled with mucus. Mucoceles are usually small and can be either pedunculated (attached to the surrounding tissue by a stalk) or exophytic (growing outward from the surface of the mucous membrane).

Synonyms: mucous cyst, mucinous cyst, mucous tumor, benign mucosal tumor.

Etymology: From Latin muco- (mucus) + cele (cyst, sac).

Examples of Mucocele in a sentence:

1. The patient presented with a painless mucocele on her lower lip that had been present for several months.
2. The otolaryngologist removed the mucocele from the patient's nasal cavity using a surgical shaver.
3. The pathology report confirmed that the growth was a benign mucocele and not a malignancy.

There are many different types of cysts that can occur in the body, including:

1. Sebaceous cysts: These are small, usually painless cysts that form in the skin, particularly on the face, neck, or torso. They are filled with a thick, cheesy material and can become inflamed or infected.
2. Ovarian cysts: These are fluid-filled sacs that form on the ovaries. They are common in women of childbearing age and can cause pelvic pain, bloating, and other symptoms.
3. Kidney cysts: These are fluid-filled sacs that form in the kidneys. They are usually benign but can cause problems if they become large or infected.
4. Dermoid cysts: These are small, usually painless cysts that form in the skin or organs. They are filled with skin cells, hair follicles, and other tissue and can become inflamed or infected.
5. Pilar cysts: These are small, usually painless cysts that form on the scalp. They are filled with a thick, cheesy material and can become inflamed or infected.
6. Epidermoid cysts: These are small, usually painless cysts that form just under the skin. They are filled with a thick, cheesy material and can become inflamed or infected.
7. Mucous cysts: These are small, usually painless cysts that form on the fingers or toes. They are filled with a clear, sticky fluid and can become inflamed or infected.
8. Baker's cyst: This is a fluid-filled cyst that forms behind the knee. It can cause swelling and pain in the knee and is more common in women than men.
9. Tarlov cysts: These are small, fluid-filled cysts that form in the spine. They can cause back pain and other symptoms, such as sciatica.
10. ganglion cysts: These are noncancerous lumps that form on the joints or tendons. They are filled with a thick, clear fluid and can cause pain, swelling, and limited mobility.

It's important to note that this is not an exhaustive list and there may be other types of cysts that are not included here. If you suspect that you have a cyst, it's always best to consult with a healthcare professional for proper diagnosis and treatment.

Pyonephrosis is a serious medical condition that requires prompt treatment to prevent long-term damage to the kidneys and potential complications such as sepsis or kidney failure. It is important for individuals with symptoms of pyonephrosis to seek medical attention as soon as possible, as early diagnosis and treatment can improve outcomes and reduce the risk of complications.

Previous article What is the main difference between a hematuria and nephritis?
Next article Can you give an example of a condition that could cause pyonephrosis?

Examples of mixed tumors include:

* Teratoma: a type of mixed tumor that contains immature tissue, such as hair follicles, sweat glands, and teeth.
* Malignant melanoma: a type of skin cancer that contains a mixture of melanocytes (pigment-producing cells) and other types of cells.
* Leiomyosarcoma: a type of uterine cancer that contains a mixture of smooth muscle cells and other types of cells.

Mixed tumors can be difficult to diagnose and treat, as they are often composed of multiple types of cells that may have different growth rates and respond differently to treatment.

Benign ovarian neoplasms include:

1. Serous cystadenoma: A fluid-filled sac that develops on the surface of the ovary.
2. Mucinous cystadenoma: A tumor that is filled with mucin, a type of protein.
3. Endometrioid tumors: Tumors that are similar to endometrial tissue (the lining of the uterus).
4. Theca cell tumors: Tumors that develop in the supportive tissue of the ovary called theca cells.

Malignant ovarian neoplasms include:

1. Epithelial ovarian cancer (EOC): The most common type of ovarian cancer, which arises from the surface epithelium of the ovary.
2. Germ cell tumors: Tumors that develop from germ cells, which are the cells that give rise to eggs.
3. Stromal sarcomas: Tumors that develop in the supportive tissue of the ovary.

Ovarian neoplasms can cause symptoms such as pelvic pain, abnormal bleeding, and abdominal swelling. They can also be detected through pelvic examination, imaging tests such as ultrasound and CT scan, and biopsy. Treatment options for ovarian neoplasms depend on the type, stage, and location of the tumor, and may include surgery, chemotherapy, and radiation therapy.

Biliary tract neoplasms refer to abnormal growths or tumors that occur in the biliary tract, which includes the liver, gallbladder, and bile ducts. These tumors can be benign (non-cancerous) or malignant (cancerous).

There are several types of biliary tract neoplasms, including:

1. Cholangiocarcinoma: This is a rare type of cancer that originates in the cells lining the bile ducts. It can occur in the liver or outside the liver.
2. Gallbladder cancer: This type of cancer occurs in the gallbladder and is relatively rare.
3. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer, which means it originates in the liver rather than spreading from another part of the body.
4. Bile duct cancer: This type of cancer occurs in the bile ducts that carry bile from the liver and gallbladder to the small intestine.

Biliary tract neoplasms can cause a variety of symptoms, including abdominal pain, jaundice (yellowing of the skin and eyes), weight loss, fatigue, and itching. These symptoms can be non-specific and may resemble those of other conditions, making diagnosis challenging.

Diagnosis of biliary tract neoplasms usually involves a combination of imaging tests such as ultrasound, CT scans, MRI, and PET scans, as well as biopsies to confirm the presence of cancer cells. Treatment options for biliary tract neoplasms depend on the type, size, location, and stage of the tumor, and may include surgery, chemotherapy, radiation therapy, or a combination of these.

Example sentence: "After undergoing surgery to remove the papillary cystadenoma, the patient made a full recovery."

Benign parotid neoplasms include:

* Pleomorphic adenoma: This is the most common type of benign parotid tumor, accounting for about 70% of all benign parotid neoplasms. It is a slow-growing tumor that usually affects people between the ages of 20 and 50.
* Warthin's tumor: This is a rare type of benign parotid tumor that usually occurs in older adults. It is a slow-growing tumor that often causes few symptoms.
* Other benign tumors: These include papillary cystadenoma, oncocytoma, and adenomyoepithelioma.

Malignant parotid neoplasms include:

* Parotid duct carcinoma: This is a rare type of cancer that arises in the main duct of the parotid gland. It usually affects older adults and can be aggressive, meaning it grows quickly and spreads to other parts of the body.
* Adenoid cystic carcinoma: This is a malignant tumor that typically affects the salivary glands, including the parotid gland. It is a slow-growing tumor that can infiltrate surrounding tissues and bone, making it difficult to treat.
* Other malignant tumors: These include acinic cell carcinoma, adenocarcinoma, and squamous cell carcinoma.

The symptoms of parotid neoplasms can vary depending on the size and location of the tumor. Common symptoms include:

* A lump or swelling in the neck or face
* Painless mass or lump in the affected gland
* Difficulty swallowing or eating
* Numbness or weakness in the face
* Pain in the ear, jaw, or neck
* Fatigue
* Weight loss

If you experience any of these symptoms, it is important to see a doctor for proper evaluation and diagnosis. A doctor may perform a physical examination, take a medical history, and order imaging tests such as CT scans, MRI scans, or ultrasound to determine the presence of a parotid neoplasm.

Treatment options for parotid neoplasms depend on the type and stage of the tumor. Surgery is usually the first line of treatment, and may involve removing the affected gland or a portion of the gland. Radiation therapy and chemotherapy may also be used to treat more aggressive tumors or those that have spread to other parts of the body.

Overall, while parotid neoplasms can be serious and potentially life-threatening, early detection and treatment can improve outcomes and help preserve facial function and appearance. It is important to seek medical attention if you experience any symptoms that may indicate a parotid neoplasm.

Pseudomyxoma peritonei can occur in anyone, but it is most common in women between the ages of 20 and 50. The exact cause of this condition is not known, but it may be linked to genetic changes or previous abdominal surgery.

Symptoms of pseudomyxoma peritonei can include abdominal pain, bloating, nausea, and vomiting. These symptoms are often persistent and can worsen over time. In some cases, the tumors can become large enough to compress nearby organs, leading to additional complications such as bowel obstruction or kidney damage.

If you suspect that you may have pseudomyxoma peritonei, your doctor will begin by performing a physical exam and taking a medical history. Imaging tests such as CT scans or PET scans may also be ordered to help visualize the tumors and determine their extent. A diagnosis of pseudomyxoma peritonei is typically made based on the presence of mucin-secreting tumors on the peritoneum, along with other characteristic features such as the absence of a primary tumor site.

Treatment for pseudomyxoma peritonei usually involves surgery to remove as many of the tumors as possible. In some cases, chemotherapy or radiation therapy may also be recommended to help shrink the tumors before surgery or to kill any remaining cancer cells after surgery.

The prognosis for pseudomyxoma peritonei is generally good if the condition is detected and treated early. However, if the tumors are allowed to grow and spread, the outlook can be poorer. In rare cases, the tumors may recur even after successful treatment.

Bile duct neoplasms refer to abnormal growths or tumors that occur in the bile ducts, which are the tubes that carry bile from the liver and gallbladder to the small intestine. Bile duct neoplasms can be benign (non-cancerous) or malignant (cancerous).

Types of Bile Duct Neoplasms:

There are several types of bile duct neoplasms, including:

1. Bile duct adenoma: A benign tumor that grows in the bile ducts.
2. Bile duct carcinoma: A malignant tumor that grows in the bile ducts and can spread to other parts of the body.
3. Cholangiocarcinoma: A rare type of bile duct cancer that originates in the cells lining the bile ducts.
4. Gallbladder cancer: A type of cancer that occurs in the gallbladder, which is a small organ located under the liver that stores bile.

Causes and Risk Factors:

The exact cause of bile duct neoplasms is not known, but there are several risk factors that may increase the likelihood of developing these tumors, including:

1. Age: Bile duct neoplasms are more common in people over the age of 50.
2. Gender: Women are more likely to develop bile duct neoplasms than men.
3. Family history: People with a family history of bile duct cancer or other liver diseases may be at increased risk.
4. Previous exposure to certain chemicals: Exposure to certain chemicals, such as thorium, has been linked to an increased risk of developing bile duct neoplasms.

Symptoms:

The symptoms of bile duct neoplasms can vary depending on the location and size of the tumor. Some common symptoms include:

1. Yellowing of the skin and eyes (jaundice)
2. Fatigue
3. Loss of appetite
4. Nausea and vomiting
5. Abdominal pain or discomfort
6. Weight loss
7. Itching all over the body
8. Dark urine
9. Pale stools

Diagnosis:

Diagnosis of bile duct neoplasms typically involves a combination of imaging tests and biopsy. The following tests may be used to diagnose bile duct neoplasms:

1. Ultrasound: This non-invasive test uses high-frequency sound waves to create images of the liver and bile ducts.
2. Computed tomography (CT) scan: This imaging test uses X-rays and computer technology to create detailed images of the liver and bile ducts.
3. Magnetic resonance imaging (MRI): This test uses a strong magnetic field and radio waves to create detailed images of the liver and bile ducts.
4. Endoscopic ultrasound: This test involves inserting an endoscope (a thin, flexible tube with a small ultrasound probe) into the bile ducts through the mouth or stomach to obtain images and samples of the bile ducts.
5. Biopsy: A biopsy may be performed during an endoscopic ultrasound or during surgery to remove the tumor. The sample is then examined under a microscope for cancer cells.

Treatment:

The treatment of bile duct neoplasms depends on several factors, including the type and stage of the cancer, the patient's overall health, and the patient's preferences. The following are some common treatment options for bile duct neoplasms:

1. Surgery: Surgery may be performed to remove the tumor or a portion of the bile duct. This may involve a Whipple procedure (a surgical procedure to remove the head of the pancreas, the gallbladder, and a portion of the bile duct), a bile duct resection, or a liver transplant.
2. Chemotherapy: Chemotherapy may be used before or after surgery to shrink the tumor and kill any remaining cancer cells.
3. Radiation therapy: Radiation therapy may be used to destroy cancer cells that cannot be removed by surgery or to relieve symptoms such as pain or blockage of the bile duct.
4. Stent placement: A stent may be placed in the bile duct to help keep it open and improve blood flow to the liver.
5. Ablation therapy: Ablation therapy may be used to destroy cancer cells by freezing or heating them with a probe inserted through an endoscope.
6. Targeted therapy: Targeted therapy may be used to treat certain types of bile duct cancer, such as cholangiocarcinoma, by targeting specific molecules that promote the growth and spread of the cancer cells.
7. Clinical trials: Clinical trials are research studies that evaluate new treatments for bile duct neoplasms. These may be an option for patients who have not responded to other treatments or who have advanced cancer.

Retroperitoneal neoplasms can occur in various locations, including the kidney, adrenal gland, pancreas, liver, spleen, and small intestine. These tumors can cause a variety of symptoms, such as abdominal pain, weight loss, fever, and difficulty urinating or passing stool.

The diagnosis of retroperitoneal neoplasms is based on a combination of imaging studies, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, and a biopsy, which involves removing a small sample of tissue from the suspected tumor and examining it under a microscope.

Treatment options for retroperitoneal neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery is often the first line of treatment, and may involve removing the tumor and any affected surrounding tissue or organs. Radiation therapy and chemotherapy may also be used to shrink the tumor before surgery or to kill any remaining cancer cells after surgery.

Some common types of retroperitoneal neoplasms include:

1. Renal cell carcinoma (RCC): a type of kidney cancer that originates in the cells that line the renal tubules.
2. Adrenocortical carcinoma: a type of cancer that arises in the adrenal gland.
3. Pancreatic neuroendocrine tumors: tumors that arise in the pancreas and produce excess hormones.
4. Liver cancer (hepatocellular carcinoma): a type of cancer that originates in the liver cells.
5. Gastrointestinal stromal tumors (GISTs): tumors that arise in the digestive system, usually in the stomach or small intestine.
6. Soft tissue sarcomas: tumors that arise in the soft tissues of the body, such as the muscles, fat, and connective tissue.
7. Retroperitoneal fibrosis: a condition where the tissue in the retroperitoneum becomes scarred and thickened.
8. Metastatic tumors: tumors that have spread to the retroperitoneum from another part of the body, such as the lung, breast, or colon.

It is important to note that this is not an exhaustive list and there may be other types of retroperitoneal neoplasms not mentioned here. If you suspect you may have a retroperitoneal neoplasm, it is important to consult with a qualified medical professional for proper diagnosis and treatment.

Pancreatic adenocarcinoma is the most common type of malignant pancreatic neoplasm and accounts for approximately 85% of all pancreatic cancers. It originates in the glandular tissue of the pancreas and has a poor prognosis, with a five-year survival rate of less than 10%.

Pancreatic neuroendocrine tumors (PNETs) are less common but more treatable than pancreatic adenocarcinoma. These tumors originate in the hormone-producing cells of the pancreas and can produce excess hormones that cause a variety of symptoms, such as diabetes or high blood sugar. PNETs are classified into two main types: functional and non-functional. Functional PNETs produce excess hormones and are more aggressive than non-functional tumors.

Other rare types of pancreatic neoplasms include acinar cell carcinoma, ampullary cancer, and oncocytic pancreatic neuroendocrine tumors. These tumors are less common than pancreatic adenocarcinoma and PNETs but can be equally aggressive and difficult to treat.

The symptoms of pancreatic neoplasms vary depending on the type and location of the tumor, but they often include abdominal pain, weight loss, jaundice, and fatigue. Diagnosis is typically made through a combination of imaging tests such as CT scans, endoscopic ultrasound, and biopsy. Treatment options for pancreatic neoplasms depend on the type and stage of the tumor but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Prognosis for patients with pancreatic neoplasms is generally poor, especially for those with advanced stages of disease. However, early detection and treatment can improve survival rates. Research into the causes and mechanisms of pancreatic neoplasms is ongoing, with a focus on developing new and more effective treatments for these devastating diseases.




1. Parotid gland tumors: These are the most common type of salivary gland tumor and can be benign or malignant.
2. Submandibular gland tumors: These are less common than parotid gland tumors but can also be benign or malignant.
3. Sublingual gland tumors: These are rare and usually benign.
4. Warthin's tumor: This is a type of benign tumor that affects the parotid gland.
5. Mucoepidermoid carcinoma: This is a type of malignant tumor that can occur in any of the major salivary glands.
6. Acinic cell carcinoma: This is a rare type of malignant tumor that usually occurs in the parotid gland.
7. Adenoid cystic carcinoma: This is a slow-growing malignant tumor that can occur in any of the major salivary glands.
8. Metastatic tumors: These are tumors that have spread to the salivary glands from another part of the body.

Salivary gland neoplasms can cause a variety of symptoms, including painless lumps or swelling in the neck or face, difficulty swallowing, and numbness or weakness in the face. Treatment options depend on the type and stage of the tumor and may include surgery, radiation therapy, and/or chemotherapy.

In conclusion, salivary gland neoplasms are a diverse group of cancers that affect the salivary glands, and it's important to be aware of the different types, symptoms, and treatment options in order to provide effective care for patients with these tumors.

... is a type of tumor in the cystadenocarcinoma grouping. It can occur in the breast as well as in the ... Honma N, Sakamoto G, Ikenaga M, Kuroiwa K, Younes M, Takubo K (August 2003). "Mucinous cystadenocarcinoma of the breast: a case ... "Ovarian mucinous cystadenocarcinoma , Radiology Reference Article". Radiopaedia.org. Retrieved 25 April 2022. v t e (Articles ...
... mucinous bronchioloalveolar carcinoma, signet ring cell adenocarcinoma, mucinous cystadenocarcinoma, and mucinous "colloid" ... may be of use in differentiating primary mucinous cystadenocarcinoma of the lung from metastatic lung tumors due to mucinous ... Mucinous cystadenocarcinoma of the lung (MCACL) is a very rare malignant mucus-producing neoplasm arising from the uncontrolled ... November 2003). "Pulmonary mucinous cystadenocarcinoma: report of a case and review of the literature". The Annals of Thoracic ...
"Primary Breast Mucinous Cystadenocarcinoma and Review of Literature". Cureus. 14 (3): e23098. doi:10.7759/cureus.23098. PMC ...
Cystadenocarcinomas can be classified into serous cystadenocarcinomas and mucinous cystadenomcarcinomas. Among the ovarian ... Papillary serous cystadenocarcinoma Ovarian serous cystadenoma "Ovarian papillary cystadenocarcinoma". Female Genital Pathology ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular epithelium, in which cystic ... A cystadenocarcinoma contains complex multi-loculated cyst but with exuberant solid areas in places. It usually presents with ...
Biliary cystadenoma and cystadenocarcinoma constitute less than 5% of intrahepatic cysts originating from the bile duct. ... ovarian mucinous cystadenoma Pancreas-pancreatic mucinous cystadenoma Peritoneum-peritoneal mucinous cystadenoma Liver-mucinous ... Pancreatic mucinous cystadenoma or mucinous cystadenoma of the pancreas (MCN) are a type of mucinous cystic neoplasm of the ... Mucinous cystadenoma is a benign cystic tumor lined by a mucinous epithelium. It is a type of cystic adenoma (cystadenoma). ...
Pancreatic mucinous cystadenoma Pancreatic mucinous cystadenocarcinoma (Articles needing additional references from January ... Pancreatic serous cystadenoma Pancreatic serous cystadenocarcinoma Pancreatic mucinous cystic tumors (13.4%) ... Pancreatic intraductal papillary mucinous tumors (most common diagnosis - 52.6%) Pancreatic serous cystic tumors (20.6%) ... Among this heterogeneous group, benign neoplasms predominate, particularly those with mucinous lining. Age at presentation, ...
... several mucinous tumors (mucinous adenocarcinoma, mucinous cystadenoma, and mucinous cystadenocarcinoma), as well as other ... Low-grade mucinous adenocarcinoma is used by the American Joint Committee on Cancer and World Health Organization and is nearly ... The term mucinous adenocarcinoma is used in different contexts depending on the reference material used by the pathologist for ... For low-grade mucinous adenocarcinoma, disease may be designated as "benign" because tumors do not invade deeply into tissue ...
... cystadenocarcinoma, mucinous MeSH C04.557.470.200.025.480.230 - cystadenocarcinoma, papillary MeSH C04.557.470.200.025.480.240 ... mucinous MeSH C04.557.470.590.480.230 - cystadenocarcinoma, papillary MeSH C04.557.470.590.480.240 - cystadenocarcinoma, serous ... mucinous, and serous MeSH C04.557.470.590.075 - adenocarcinoma, mucinous MeSH C04.557.470.590.340 - carcinoma, mucoepidermoid ... mucinous MeSH C04.557.470.035.320.230 - cystadenoma, papillary MeSH C04.557.470.035.320.240 - cystadenoma, serous MeSH C04.557. ...
Sebaceous carcinoma Sebaceous lymphadenocarcinoma Cystadenocarcinoma Low-grade cribriform cystadenocarcinoma Mucinous ...
... mucinous/serous) Cystadenocarcinoma Islet cell tumors (neuroendocrine tumors) Papillary cystic neoplasms Lymphoma Acinar cell ...
... borderline malignancy Serous carcinoma Well differentiated endometrioid tumor Mucinous cystadenoma Mucinous cystadenocarcinoma ...
Endometrioid cystadenoma (8380) Appendix: The term mucinous cystadenoma is an obsolete term for appendiceal mucinous neoplasm ... When malignant, it is called cystadenocarcinoma. When not otherwise specified, the ICD-O coding is 8440/0. However, the ... "Appendix - Other tumors - Mucinous neoplasms (LAMN and HAMN)". Topic Completed: 1 October 2017. Revised: 11 December 2019 ... ISBN 978-1-4160-2999-1. Serous cystadenoma of pancreas at eMedicine Biliary cystadenoma/cystadenocarcinoma at eMedicine v t e ( ...
Mucinous tumors include mucinous adenocarcinoma and mucinous cystadenocarcinoma. Mucinous adenocarcinomas make up 5-10% of ... Advanced mucinous adenocarcinomas have a poor prognosis, generally worse than serous tumors, and are often resistant to ... Estrogen HRT with or without progestins increases the risk of endometrioid and serous tumors but lowers the risk of mucinous ... Almost 100% of rare mucinous carcinomas have mutations in KRAS and amplifications of ERBB2 (also known as Her2/neu). Overall, ...
As primary ovarian mucinous tumors are usually unilateral (in one ovary), the presentation of bilateral mucinous tumors ... 75% are benign or of borderline malignancy, and 25% are malignant The malignant form of this tumor, serous cystadenocarcinoma, ... of primary mucinous tumors are bilateral. May form very large cystic masses, with recorded weights exceeding 25 kg Mucinous ... Mucinous tumors: Closely resemble their serous counterparts but unlikely to be bilateral Somewhat less common, accounting for ...
... such as the intraductal papillary mucinous neoplasm and the pancreatic mucinous cystadenoma), serous cystic neoplasms are ... "serous cystadenocarcinoma".[citation needed] These lesions rarely require surgery unless they are symptomatic or the diagnosis ... Ovarian serous cystadenoma Pancreatic mucinous cystadenoma Solid pseudopapillary neoplasm Jais B, Rebours V, Malleo G, Salvia R ...
M8470/2 Mucinous cystadenocarcinoma, non-invasive (C25._) M8470/3 Mucinous cystadenocarcinoma/ NOS (C56.9) Pseudomucinous ... NOS M8471/3 papillary mucinous cystadenocarcinoma (C56.9) Papillary pseudomucinous cystadenocarcinoma M8472/1 Mucinous cystic ... Papillary mucinous tumor of low malignant potential M8480/0 Mucinous adenoma M8480/3 Mucinous adenocarcinoma Mucinous carcinoma ... M9015/3 Mucinous adenocarcinofibroma Malignant mucinous adenofibroma Mucinous cystadenocarcinofibroma Malignant mucinous ...
The 2014 Ju-Jitsu World Championship were the 12th edition of the Ju-Jitsu World Championships, and were held in Paris, France from November 28 to November 30, 2014. 28.11.2014 - Men's and Women's Fighting System, Men's and Women's Jiu-Jitsu (ne-waza), Men's Duo System - Classic 29.11.2014 - Men's and Women's Fighting System, Men's and Women's Jiu-Jitsu (ne-waza), Women's Duo System - Classic 30.11.2014 - Men's Jiu-Jitsu (ne-waza), Mixed Duo System - Classic, Team event Vincent MATCZAK (2014-09-30). "4TH INVITAION TO WORLD CHAMPIONSHIP 2014" (PDF). Retrieved 2019-11-28.[dead link] Online results Official results (PDF) Mixed team event results (PDF) (All articles with dead external links, Articles with dead external links from April 2022, Ju-Jitsu World Championships, 2014 in French sport ...
Bolley L. "Bo" Johnson (born November 15, 1951) is an American politician from the state of Florida. A member of the Democratic Party, Johnson was a member of the Florida House of Representatives, and served as the Speaker of the Florida House of Representatives. Johnson is from Milton, Florida. His father and grandfather served as county commissioners for Santa Rosa County, Florida. Johnson graduated from Milton High School, and became the first member of his family to attend college. He received his bachelor's degree from Florida State University. Johnson volunteered for Mallory Horne when Horne served as the president of the Florida Senate. At the age of 22, Johnson met Lawton Chiles, then a member of the United States Senate, who hired him as a legislative aide in 1973. Johnson was elected to the Florida House of Representatives, representing the 4th district from November 7, 1978 to November 3, 1992. He also served the 1st district from November 3, 1992 to November 8, 1994. He became the ...
... may refer to: Don't Say No (Billy Squier album), a 1981 album by American rock singer Billy Squier, and its title track Don't Say No (Seohyun EP), a 2016 extended play by South Korean pop singer Seohyun, and its title track "Don't Say No" (Tom Tom Club song), from the 1988 album Boom Boom Chi Boom Boom "Don't Say No", by Robbie Williams from the 2005 album Intensive Care "Don't Say No Tonight", a 1985 single by Eugene Wilde This disambiguation page lists articles associated with the title Don't Say No. If an internal link led you here, you may wish to change the link to point directly to the intended article. (Disambiguation pages with short descriptions, Short description is different from Wikidata, All article disambiguation pages, All disambiguation pages, Disambiguation pages ...
The Dewoitine 37 was the first of a family of 1930s French-built monoplane fighter aircraft. The D.37 was a single-seat aircraft of conventional configuration. Its fixed landing gear used a tailskid. The open cockpit was located slightly aft of the parasol wing. The radial engine allowed for a comparatively wide fuselage and cockpit. Design of this machine was by SAF-Avions Dewoitine but owing to over work at that companies plant at the time, manufacture of the D.37/01 was transferred to Lioré et Olivier. They were high-wing monoplanes of all-metal construction with valve head blisters on their engine cowlings. The first prototype flew in October 1931. Flight testing resulted in the need for multiple revisions in both engine and airframe, so it was February 1934 before the second prototype flew. Its performance prompted the French government to order for 28 for the Armée de l'Air and Aéronavale. The Lithuanian government ordered 14 that remained in service with their Air Force until 1936, ...
The Noor-ul-Ain (Persian: نور العين, lit. 'the light of the eye') is one of the largest pink diamonds in the world, and the centre piece of the tiara of the same name. The diamond is believed to have been recovered from the mines of Golconda, Hyderabad in India. It was first in possession with the nizam Abul Hasan Qutb Shah, later it was given as a peace offering to the Mughal emperor Aurangazeb when he defeated him in a siege. It was brought into the Iranian Imperial collection after the Persian king Nader Shah Afshar looted Delhi in the 18th century.[citation needed] The Noor-ul-Ain is believed to have once formed part of an even larger gem called the Great Table diamond. That larger diamond is thought to have been cut in two, with one section becoming the Noor-ul-Ain and the other the Daria-i-Noor diamond. Both of these pieces are currently part of the Iranian Crown Jewels. The Noor-ul-Ain is the principal diamond mounted in a tiara of the same name made for Iranian Empress Farah ...
The Benoist Land Tractor Type XII was one of the first enclosed cockpit, tractor configuration aircraft built. Benoist used "Model XII" to several aircraft that shared the same basic engine and wing design, but differed in fuselage and control surfaces. The Type XII was a tractor-engined conversion of the model XII headless pusher aircraft that resembled the Curtiss pusher aircraft. Demonstration pilots used Benoist aircraft to demonstrate the first parachute jumps, and the tractor configuration was considered much more suitable for the task. The first example named the "Military Plane" had a small box frame covered fuselage that left the occupants mostly exposed to the wind. The later model XII "Cross Country Plane" had a full fuselage that occupants sat inside of. The first tractor biplane used a wooden fuselage with a small seat on top. The wings were covered with a Goodyear rubberized cloth. The first model XII was built in the spring of 1912. On 1 March 1912, Albert Berry used a headless ...
... (also known as Yalmotx in Qʼanjobʼal) is a town, with a population of 17,166 (2018 census), and a municipality in the Guatemalan department of Huehuetenango. It is situated at 1450 metres above sea level. It covers a terrain of 1,174 km². The annual festival is April 29-May 4. Barillas has a tropical rainforest climate (Af) with heavy to very heavy rainfall year-round and extremely heavy rainfall from June to August. Citypopulation.de Population of departments and municipalities in Guatemala Citypopulation.de Population of cities & towns in Guatemala "Climate: Barillas". Climate-Data.org. Retrieved July 26, 2020. Muni in Spanish Website of Santa Cruz Barillas Coordinates: 15°48′05″N 91°18′45″W / 15.8014°N 91.3125°W / 15.8014; -91.3125 v t e (Articles with short description, Short description is different from Wikidata, Pages using infobox settlement with no coordinates, Articles containing Q'anjob'al-language text, Coordinates on Wikidata, ...
Maria Margaret La Primaudaye Pollen (10 April 1838 - c. 1919), known as Minnie, was a decorative arts collector. As Mrs John Hungerford Pollen, she became known during the early-twentieth century as an authority on the history of textiles, publishing Seven Centuries of Lace in 1908. Maria Margaret La Primaudaye was born into a Huguenot family on 10 April 1838, the third child of the Revd Charles John La Primaudaye, a descendant of Pierre de La Primaudaye. She was educated in Italy. Her family converted to Catholicism in 1851, and it was in Rome that her father met another recent English convert, John Hungerford Pollen, previously an Anglican priest and a decorative artist. She became engaged to Pollen, who was then seventeen years her senior, in the summer of 1854, and was married in the church of Woodchester monastery, near Stroud, Gloucester, on 18 September 1855. The Pollens initially settled in Dublin, where John Hungerford Pollen had been offered the professorship of fine arts at the ...
Ronald Robert Fogleman (born January 27, 1942) is a retired United States Air Force general who served as the 15th Chief of Staff of the Air Force from 1994 to 1997 and as Commanding General of the United States Transportation Command from 1992 to 1994. A 1963 graduate from the United States Air Force Academy, he holds a master's degree in military history and political science from Duke University. A command pilot and a parachutist, he amassed more than 6,800 flying hours in fighter, transport, tanker and rotary wing aircraft. He flew 315 combat missions and logged 806 hours of combat flying in fighter aircraft. Eighty of his missions during the Vietnam War were as a "Misty FAC" in the F-100F Super Sabre at Phù Cát Air Base, South Vietnam between 25 December 1968 and 23 April 1969. Fogleman was shot down in Vietnam in 1968, while piloting an F-100. He was rescued by clinging to an AH-1 Cobra attack helicopter that landed at the crash site. In early assignments he instructed student pilots, ...
Peachtree Street" is a 1950 song co-written and recorded by Frank Sinatra in a duet with Rosemary Clooney. The song was released as a Columbia Records single. Frank Sinatra co-wrote the song with Leni Mason and Jimmy Saunders. Mason composed the music while Sinatra and Saunders wrote the lyrics. The song was arranged by George Siravo The song was released as an A side Columbia 10" 78 single, Catalog Number 38853, Matrix Number CO-43100-1 and as a 7" 33, 1-669. The B side was the re-issued "This Is the Night." Neither of the songs charted. The subject of the song is a stroll down the street in Atlanta, Georgia of the same name. Sinatra originally intended Dinah Shore to sing the duet with him. When Shore declined, Clooney was asked. The song was recorded on April 8, 1950. The song features spoken asides by Sinatra and Clooney. Rosemary Clooney asks: "Say, Frank, you wanna take a walk?" Frank Sinatra replies: "Sure, sweetie, just pick a street." He noted how there were no peach trees on the ...
... is a painting by American illustrator Norman Rockwell that depicts a Boy Scout in full uniform standing in front of a waving American flag. It was originally created by Rockwell in 1942 for the 1944 Brown & Bigelow Boy Scout Calendar. The model, Bob Hamilton, won a contest to be in the painting and personally delivered a print to the Vice President of the United States at the time, Henry A. Wallace. The painting was created to encourage Scouts to participate in the war effort during World War II. The name of the painting, We, Too, Have a Job to Do, comes from a slogan that the Boy Scouts of America used in 1942 to rally scouts to support the troops by collecting metal and planting victory gardens. The model, Bob Hamilton, won a contest with his local council in Albany, New York, to be depicted in the painting. He traveled to Rockwell's studio in Arlington, Vermont, to model for Rockwell. Since Hamilton was a scout, the uniform shown in the painting was his, unlike some ...
At least 33[failed verification] people were killed by a fuel tanker explosion in Tleil, Akkar District, Lebanon on 15 August 2021. The disaster was reportedly exacerbated by the ongoing Lebanese liquidity crisis; in which the Lebanese pound has plummeted and fuel has been in short supply. The survivors were evacuated by the Lebanese Red Cross. An investigation is underway. The fuel tanker had been confiscated by the Lebanese Armed Forces from black marketeers, the fuel was then distributed/taken by the locals. The son of the man whose land the fuel tanker was located on, was later arrested, accused of deliberately causing the explosion. Agencies (2021-08-15). "At least 20 killed and 79 injured in fuel tank explosion in Lebanon". the Guardian. Retrieved 2021-08-15. "Lebanon fuel explosion kills 22 and injures dozens more". The Independent. 2021-08-15. Archived from the original on 2021-08-15. Retrieved 2021-08-15. "Lebanon: At least 20 dead and dozens injured after fuel tank explodes as ...
The Straubing Tigers are a professional men's ice hockey team, based in Straubing, Germany, that competes in the Deutsche Eishockey Liga. Straubing plays its home games at the Eisstadion am Pulverturm, which has a capacity of 5,800 spectators. Promoted to the DEL in 2006, and operating with one of the league's smallest budgets, the team could finish no better than twelfth before the 2011-12 DEL season, when it reached the semi-finals of the playoffs. Their greatest success so far is the qualification for the season 2020-21 of the Champions Hockey League. In 1941, the then 14-year-old Max Pielmaier and his friends Max Pellkofer and Harry Poiger founded the first hockey team in Straubing. The first official game took place on the first of February 1942 in Hof and was lost by a score of 0:1. In the following year there were several games against other Bavarian teams. The game against Landshut on 31 January. 1943 was the last game during the second World War, because the young players also had to ...
Leina is a village in Saaremaa Parish, Saare County in western Estonia. Before the administrative reform in 2017, the village was in Pihtla Parish. "Lisa. Asustusüksuste nimistu" (PDF). haldusreform.fin.ee (in Estonian). Rahandusministeerium. Retrieved 5 December 2017. "Saaremaa külad endiste valdade piires". www.saaremaa.ee (in Estonian). Archived from the original on 3 December 2017. Retrieved 5 December 2017. Coordinates: 58°17′10″N 22°46′26″E / 58.28611°N 22.77389°E / 58.28611; 22.77389 v t e (CS1 Estonian-language sources (et), Articles with short description, Short description is different from Wikidata, Pages using infobox settlement with no map, Pages using infobox settlement with no coordinates, Saaremaa Parish, Coordinates on Wikidata, Villages in Saare County, All stub articles, Saare County geography stubs ...
MARIANO, Ronaldo Célio et al. Papillary mucinous cystadenocarcinoma: rare malignant tumor in minor salivary gland. RGO, Rev. ... was diagnosed as papillary mucinous papillary mucinous cystadenocarcinoma. Nonetheless, the cellular atypia found was ... Clinical case description of a papillary mucinous cystadenocarcinoma, extremely rare malignant tumor in the salivary gland and ...
A Ruptured Mucinous Cystadenocarcinoma of the Pancreas Extensively Evaluated Before and After the Rupture: A Case Report. ... A Ruptured Mucinous Cystadenocarcinoma of the Pancreas Extensively Evaluated Before and Af ... The histopathological diagnosis was noninvasive mucinous cystadenocarcinoma. At 9 months after surgery, she started ... ABSTRACT Pancreatic mucinous cystic neoplasm (MCN) rarely ruptures because of their surrounding fibrotic capsules and has never ...
Mucinous cystadenocarcinoma of panceas. Discussion: Typical mucinous tumor with large cystic mass in the head (may be in the ...
Histology reported a mucinous cystadenocarcinoma of low malignant potential. Image courtesy of C. William Helm, MBBChir. ... Histology reported a mucinous cystadenocarcinoma of low malignant potential. Courtesy Patrick OKane, MD. ... No generalized screening test is available for ovarian cystadenocarcinoma, but women at high risk based on family history or a ... Women at high risk for ovarian cystadenocarcinoma may be offered prophylactic oophorectomy, which will prevent the development ...
mucinous appendiceal cystadenocarcinoma Sat Oct 14, 2006 10:44 am. Majafrytka. 136. Appendix cancer - Appendiceal Moderator ...
8. Rare Pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma 9. ... 7. Fibromixoma and low-grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary ... or invasive mucinous adenocarcinoma) 13. Non-epithelial tumors of the ovary 14. Trophoblastic tumor 15. Transitional cell ...
Cystic, Mucinous And Serous (8440-8499). (Mucoepidermoid carcinoma - Cystadenoma/Cystadenocarcinoma/Pseudomyxoma peritonei - ...
Although CA125 expressed a remarkable diagnostic efficiency with serous cystadenocarcinoma, it was less efficient with mucinous ... especially for monitoring mucinous cystadenocarcinoma, and it is localized in the microvilli and apical cytoplasmic membrane of ... of mucinous cystadenocarcinomas and 66.7% of serous cystadenocarcinomas), while specificity of benign ovarian tumors was 91.1 ... staining with MAbs B72.3 and CC49 in the cytoplasm was stronger than that in the cell membrane in tissues from mucinous ...
Cystadenocarcinoma, Mucinous Entry term(s). Cystadenocarcinomas, Mucinous Mucinous Cystadenocarcinoma Mucinous ... Cystadenocarcinomas, Mucinous. Mucinous Cystadenocarcinoma. Mucinous Cystadenocarcinomas. Tree number(s):. C04.557.470.200. ... Cystadenocarcinoma, Mucinous - Preferred Concept UI. M0027513. Scope note. A malignant cystic or semisolid tumor most often ... This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar ...
Cystadenocarcinoma [C04.557.470.200.025.480] * Cystadenocarcinoma, Mucinous [C04.557.470.200.025.480.225] * Cystadenocarcinoma ... Cystadenocarcinoma [C04.557.470.590.480] * Cystadenocarcinoma, Mucinous [C04.557.470.590.480.225] * Cystadenocarcinoma, ... Cystadenocarcinoma, Mucinous Preferred Term Term UI T054585. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1994). ... Cystadenocarcinoma, Mucinous Preferred Concept UI. M0027513. Scope Note. A malignant cystic or semisolid tumor most often ...
Neoplastic transformation of endocervicosis into an extraovarian mucinous cystadenocarcinoma. Kruse, A-J., Slangen, B., ...
mucinous adenocarcinoma cell line:JHOM-1.CNhs11752.10648-109A9. 0.00. mucinous cystadenocarcinoma cell line:MCAS. ... serous cystadenocarcinoma cell line:HTOA.CNhs11827.10693-109F9. 0.00. signet ring carcinoma cell line:Kato III.CNhs10753.10436- ...
... and patients with endometrioid cystadenocarcinoma had higher PF RANTES levels than women with mucinous cystadenocarcinoma. We ... Women with serous cystadenocarcinoma, clear cell carcinoma and endometrioid cystadenocarcinoma had significantly higher PF ...
Cystadenocarcinoma, Mucinous 1 0 Cystadenocarcinoma, Serous 1 0 Myelodysplastic Syndromes 1 0 ...
Mucinous cystadenocarcinoma (morphologic abnormality). Code System Preferred Concept Name. Mucinous cystadenocarcinoma ( ...
Mucinous Cystadenocarcinoma of Ovary: 10 Years Experience of a Tertiary Cancer Institute, ahpgic. *Author:Manoranjan mohapatra ... ABSTRACT: To calculate the incidence of mucinous cystadenocarcinoma of ovary in the institute and to analyze the preop, intraop ... Eligibility criteria includes histopathologically and IHC diagnosed Primary mucinous cystadenocarcinoma of ovary. Secondary ... ovarian mucinous and borderline ovarian mucinous were excluded. Kaplan meyesrs survival methodand regression analysis was used ...
Label: ovarian mucinous cystadenocarcinoma Synonyms: ovarian mucinous cystadenocarcinoma Alternative IDs: als API: GO ...
Mucinous cystadenocarcinoma (↑ risk of perforation). *. Pseudomyxoma peritonei. *. Due to rupture: Malignant , benign mucocele ...
Cystadenocarcinoma, Mucinous 3 0 Cystadenoma, Mucinous 3 0 Leukemia 3 1 Leukemia, Myelomonocytic, Juvenile 3 0 ...
Giant Mucinous Ovarian Cystadenocarcinoma. F. Konjić, Z. Rifatbegović, M. Pirić, Š. Hasukić ...
Splenic mucinous cystadenocarcinoma arising in heterotopic pancreatic tissue. G Zanetti, L Riccioni, C Gallo, N Salfi, GN ... Pseudomyxoma peritonei associated with intraductal papillary-mucinous neoplasm of the pancreas. M Zanelli, R Casadei, D Santini ...
A case of skin metastasis of ovarian cancer (mucinous cystadenocarcinoma). Korean J Dermatol 2010;48:342-345. ...
... mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. ... or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed ... Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/ ...
Mucinous cystadenocarcinoma is a type of Ovarian Epithelial tumour and only 5-10% are malignant. These tumours are filled with ... mucinous material and if the tumour ruptures it can lead to Psuedomyxoma Peritonei. 5406k. v. 2 Sep 2, 2011, 2:00 AM Webmaster ...
Mucinous cystadenocarcinoma was the ommonest malignant ovarian tumour 14(35) and was closely followed by granulosa cell tumour ... 10(25); dysgerminoma 17.5); serous cystadenocarcinoma (12.5); malignant teratoma 2(5) and endodermal sinus tumour (5). There ...
Giant mucinous cystadenocarcinoma of the ovary with cavitary metastases to lungs in a postmenopausal woman: A rare presentation ...
Topics included a pulmonary mucinous adenocarcinoma in a mouse; plexiform vasculopathy in rats; staging of the estrous cycle in ... ovarian cystadenocarcinoma, retro-orbital schwannoma, periductal cholangiofibrosis of the liver and pancreas, pars distalis ... gallbladder mucinous hyperplasia, focus of hepatocellular alteration and bile duct alteration in otters, renal tubule ...
  • This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. (nih.gov)
  • Serous cystadenoma (52.7%) was the commonest benign tumor followed by Mucinous Modi D, Rathod GB, Delwadia KN, Goswami HM. (who.int)
  • Serous cystadenoma was the most common ovarian tumor overall as well as the most common benign tumor, whereas serous cystadenocarcinoma was the most common ovarian malignancy. (who.int)
  • ABSTRACT Pancreatic mucinous cystic neoplasm (MCN) rarely ruptures because of their surrounding fibrotic capsules and has never been reported with detailed information regarding prerupture and postrupture states. (bvsalud.org)
  • 6. Primary Retroperitoneal Mucinous Cystic Neoplasm: Authors' Experience and Review of the Literature. (nih.gov)
  • Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. (uci.edu)
  • This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. (uci.edu)
  • 10. Primary retroperitoneal mucinous cystadenocarcinomas are a distinct entity. (nih.gov)
  • Immunohistochemical staining with MAbs B72.3 and CC49 in the cytoplasm was stronger than that in the cell membrane in tissues from mucinous cystadenocarcinomas. (nih.gov)
  • Typical mucinous tumor with large cystic mass in the head (may be in the body or tail) and minimal solid component causing bile duct and pancreatic duct obstruction. (radiopaedia.org)
  • Biliary mucinous cystic neoplasms (BMCNs) are uncommon neoplastic septated intrahepatic cysts which are often incorrectly diagnosed and have the potential for malignant transformation. (who.int)
  • had frozen section performed on the cyst wall intraoperatively, all confirming mucinous neoplasms. (who.int)
  • Clinical case description of a papillary mucinous cystadenocarcinoma, extremely rare malignant tumor in the salivary gland and difficult to diagnose, in geriatric patient. (bvsalud.org)
  • Despite the favorable clinical features, after surgical removal, was diagnosed as papillary mucinous papillary mucinous cystadenocarcinoma. (bvsalud.org)
  • Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. (uci.edu)
  • A Ruptured Mucinous Cystadenocarcinoma of the Pancreas Extensively Evaluated Before and After the Rupture: A Case Report. (bvsalud.org)
  • 13. Mucinous cystadenocarcinoma of the pancreas during pregnancy. (nih.gov)
  • Topics included aging mouse lesions from various strains, as well as the following lesions from various rat strains: rete testis sperm granuloma/fibrosis, ovarian cystadenocarcinoma, retro-orbital schwannoma, periductal cholangiofibrosis of the liver and pancreas, pars distalis hypertrophy, chronic progressive nephropathy, and renal tubule regeneration. (nih.gov)
  • To calculate the incidence of mucinous cystadenocarcinoma of ovary in the institute and to analyze the preop, intraop and post op characteristics and analyzing the disease free survival disease free survival(dfs) and overall survival (OS )of the cases.It is a retrospective study done in the institute consisting of patients between 2009-2019. (icrrd.com)
  • Eligibility criteria includes histopathologically and IHC diagnosed Primary mucinous cystadenocarcinoma of ovary. (icrrd.com)
  • Mucinous cystadenocarcinoma is a type of Ovarian Epithelial tumour and only 5-10% are malignant. (ijmch.org)
  • Tumor quístico o semisólido, maligno, que ocurre con mayor frecuencia en el ovario. (bvsalud.org)
  • Consequently, TAG-72 was useful for the detection of ovarian carcinoma, especially for monitoring mucinous cystadenocarcinoma, and it is localized in the microvilli and apical cytoplasmic membrane of cystadenocarcinoma cells. (nih.gov)
  • Women with serous cystadenocarcinoma, clear cell carcinoma and endometrioid cystadenocarcinoma had significantly higher PF RANTES levels than patients with undifferentiated carcinoma. (hilarispublisher.com)
  • 1. Primary retroperitoneal mucinous cystadenocarcinoma during pregnancy. (nih.gov)
  • 2. Primary retroperitoneal mucinous cystadenocarcinoma associated with pregnancy. (nih.gov)
  • 3. Primary retroperitoneal mucinous cystadenocarcinoma in pregnancy - case report. (nih.gov)
  • 5. Management of a primary retroperitoneal mucinous cystadenocarcinoma: case report. (nih.gov)
  • 7. Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. (nih.gov)
  • 14. [Primary retroperitoneal mucinous cystadenocarcinoma]. (nih.gov)
  • 15. Primary retroperitoneal mucinous cystadenocarcinoma with mural nodules: a case report and literature review. (nih.gov)
  • 16. Primary mucinous cystadenocarcinoma of the retroperitoneum. (nih.gov)
  • 18. Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. (nih.gov)
  • These tumours are filled with mucinous material and if the tumour ruptures it can lead to Psuedomyxoma Peritonei. (ijmch.org)
  • En 11 annees (1er janvier 1998-31 decembre 2008) 9946 patientes ont ete operes dans notre servie dont 29 pour le cancer de l'ovaire soit 0;29. (bvsalud.org)
  • Also, histological localization of TAG-72 in the microvilli and apical cytoplasmic membrane was demonstrated by electron microscopy using MAb B72.3 and samples of seromucinous cystadenocarcinoma (mixed type). (nih.gov)
  • 4. Retroperitoneal mucinous cystadenocarcinoma in a man: case report and review of the literature. (nih.gov)
  • 8. [A case of retroperitoneal mucinous cystadenocarcinoma]. (nih.gov)
  • 20. [A Case of Mucinous Cystadenocarcinoma of the Retroperitoneum Supposed to Be Derived from Ectopic Ovarian Tissue]. (nih.gov)